According to Jim Cramer, investors should consider purchasing shares of Hinge Health following their outstanding quarterly performance.

HNGE · Hinge Health, Inc.

The AI's read

Hinge posted better-than-expected sales, raised FY2026 guide, and announced a $105m acquisition, then got a live endorsement from Jim Cramer. The story is fresh and company-specific, so it matters for stock-level moves. The market has barely reacted. HNGE is down ~0.6% since the headlines and RSI is 21.99, which reads as oversold not overheated. We lean bullish. Guide lift plus acquisition and a high-profile endorsement create asymmetric upside, but conviction is tempered by a choppy market so size positions smaller than usual.